Paperpal Prime Logo

Drugs - Real World Outcomes : Impact Factor & More

eISSN: 2198-9788pISSN: 2199-1154
JournalOpen Access

Key Metrics

CiteScore
2.7
H-Index
19
SJR
Q2Pharmacology (medical)
SNIP
0.87
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on Drugs - Real World Outcomes

Drugs - Real World Outcomes Journal Specifications

Overview
Publisher SPRINGERNATURE
Language English
Frequency Quarterly
Article Processing ChargesEUR 2190 | USD 2690 | GBP 1890
Publication Time8
Editorial Review ProcessAnonymous peer review
General Details
LanguageEnglish
FrequencyQuarterly
Publication Start Year2014
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 8
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessAnonymous peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY-NC
OA statementVisit website
View less

Planning to publish in Drugs - Real World Outcomes ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in Drugs - Real World Outcomes

Opioid Therapy Discontinuation in General Practice: Associations with Adjunct Therapies and Somatoform Pain Disorders.
  • 3 Aug 2026
  • Drugs - real world outcomes
Real-World Effectiveness and Safety of Dotinurad in Chinese Patients with Gout: A Comparative Analysis.
  • 31 Jul 2026
  • Drugs - real world outcomes
Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa: An Observational Cohort Study Based on Insurance Claims in the USA.
  • 29 Jul 2026
  • Drugs - real world outcomes
Feasibility of Reconstructing Survival Outcomes from Unstructured Electronic Medical Records under Japan's Next-Generation Medical Infrastructure Act: A Historical Cohort Study of Atezolizumab in Non-small Cell Lung Cancer.
  • 23 Jul 2026
  • Drugs - real world outcomes
Calcitonin Gene-Related Peptide Monoclonal Antibody Utilization and Treatment Gaps in People with Migraine in Japan: Results from the OVERCOME (Japan) 2nd Study.
  • 23 Jul 2026
  • Drugs - real world outcomes
Treatment Selection Patterns and Associated Outcomes for Biguanides and SGLT2 Inhibitors in Type 2 Diabetes: A Retrospective Database Study in Japan.
  • 13 Jul 2026
  • Drugs - real world outcomes
Opioid Therapy Discontinuation in General Practice: Associations with Adjunct Therapies and Somatoform Pain Disorders.
  • 3 Aug 2026
  • Drugs - real world outcomes
Real-World Effectiveness and Safety of Dotinurad in Chinese Patients with Gout: A Comparative Analysis.
  • 31 Jul 2026
  • Drugs - real world outcomes
Residual Burden in Adalimumab-Treated Patients with Hidradenitis Suppurativa: An Observational Cohort Study Based on Insurance Claims in the USA.
  • 29 Jul 2026
  • Drugs - real world outcomes
Feasibility of Reconstructing Survival Outcomes from Unstructured Electronic Medical Records under Japan's Next-Generation Medical Infrastructure Act: A Historical Cohort Study of Atezolizumab in Non-small Cell Lung Cancer.
  • 23 Jul 2026
  • Drugs - real world outcomes
Calcitonin Gene-Related Peptide Monoclonal Antibody Utilization and Treatment Gaps in People with Migraine in Japan: Results from the OVERCOME (Japan) 2nd Study.
  • 23 Jul 2026
  • Drugs - real world outcomes
Treatment Selection Patterns and Associated Outcomes for Biguanides and SGLT2 Inhibitors in Type 2 Diabetes: A Retrospective Database Study in Japan.
  • 13 Jul 2026
  • Drugs - real world outcomes

FAQs on Drugs - Real World Outcomes